InMed Pharmaceuticals

Historical price data

InMed Pharmaceuticals is executing a dual-pillar strategy to de-risk its business model: developing proprietary cannabinoid-based drug candidates for diseases with high unmet need and manufacturing rare cannabinoids for commercial and research use. Its core differentiator is the IntegraSyn™ biosynthesis platform, which enables scalable, consistent production of cannabinoids difficult to source from plants. Key achievements include advancing its lead candidate, INM-755, into clinical trials for epidermolysis bullosa and establishing its capabilities as a potential supplier in the rare cannabinoid market. The company's mission is to apply rigorous pharmaceutical development to cannabinoids, transforming them into defined, reproducible medicines.

IntegraSyn™ is a proprietary biosynthesis platform that uses engineered E. coli bacteria for the scalable, consistent, and cost-effective production of rare cannabinoids, overcoming the limitations of traditional plant extraction.

Faces competition in EB from gene/cell therapies and in glaucoma from large pharma's pressure-lowering drugs. Differentiation lies in INM-755's topical symptomatic approach and INM-088's neuroprotective mechanism. In biosynthesis, competes with other fermentation-based producers on platform efficiency and cost.